Pacific Biosc Financials
Pacific Biosc (PACB) reported $159.3M in revenue over the twelve months to Jun 30, 2026, up 2.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pacific Biosciences’ 2025 results show noncash charges separating accounting loss from cash outflow while liabilities nearly consume equity.
Earnings quality diverged sharply: FY2025 net loss was-$546M while operating cash flow was-$111M . The$382M depreciation and amortization charge explains much of that gap, so reported earnings substantially overstate the period’s cash consumption even though cash generation remained negative.
The FY2025 gross-margin recovery to
Balance-sheet leverage became highly concentrated: by FY2025, total liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Pacific Biosc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Pacific Biosc scores -6.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($397.9M) relative to total liabilities ($778.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Pacific Biosc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Pacific Biosc reported a net loss of $546.4M while operations used $111.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Pacific Biosc reported an operating loss of $553.9M against $7.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Pacific Biosc generated $160.0M in revenue in fiscal year 2025. This represents an increase of 3.9% from the prior year.
Pacific Biosc's EBITDA was -$171.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 60.4% from the prior year.
Pacific Biosc reported -$546.4M in net income in fiscal year 2025. This represents a decrease of 76.3% from the prior year.
Cash & Balance Sheet
Pacific Biosc recorded an outflow of $113.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 46.3% from the prior year.
Pacific Biosc held $63.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Pacific Biosc paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
Pacific Biosc's gross margin was 28.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 4.4 percentage points from the prior year.
Pacific Biosc's ROE was -10215.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10153.8 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Pacific Biosc invested $97.3M in research and development in fiscal year 2025. This represents a decrease of 27.9% from the prior year.
Pacific Biosc invested $2.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 56.1% from the prior year.
Not reported for fiscal year 2025.
PACB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.0M+4.9% | $37.2M-16.7% | $44.6M+16.1% | $38.4M-3.3% | $39.8M+7.0% | $37.2M-5.3% | $39.2M-1.9% | $40.0M |
| Cost of Revenue | $26.4M+8.3% | $24.3M-13.3% | $28.1M+24.6% | $22.5M-10.1% | $25.1M-34.9% | $38.5M+32.1% | $29.2M-2.7% | $30.0M |
| Gross Profit | $12.6M-1.6% | $12.8M-22.5% | $16.6M+4.2% | $15.9M+8.3% | $14.7M+1171.0% | -$1.4M-113.6% | $10.1M+0.5% | $10.0M |
| R&D Expenses | $23.0M+17.4% | $19.6M-14.3% | $22.9M+0.1% | $22.8M+1.4% | $22.5M-22.5% | $29.1M+5.8% | $27.5M+7.6% | $25.5M |
| SG&A Expenses | $33.4M+7.2% | $31.2M-8.5% | $34.1M+9.5% | $31.1M-14.0% | $36.2M-9.9% | $40.2M-3.5% | $41.6M-4.8% | $43.7M |
| Operating Income | -$44.6M-433.8% | -$8.4M+79.7% | -$41.2M-6.0% | -$38.9M+13.3% | -$44.9M+89.5% | -$428.9M-180.3% | -$153.0M-138.8% | -$64.1M |
| Interest Expense | $2.1M+21.3% | $1.7M0.0% | $1.7M+0.1% | $1.7M+0.1% | $1.7M+0.1% | $1.7M-37.0% | $2.8M-22.1% | $3.5M |
| Income Tax | $58K-68.5% | $184K-8.9% | $202K-47.3% | $383K+994.3% | $35K+111.6% | -$302K-195.6% | $316K | $0 |
| Net Income | -$44.7M-440.7% | -$8.3M+79.5% | -$40.4M-6.3% | -$38.0M+9.4% | -$41.9M+90.2% | -$426.1M-18449.5% | $2.3M+103.8% | -$60.7M |
| EPS (Diluted) | -$0.14-366.7% | -$0.03+76.9% | -$0.130.0% | -$0.13+7.1% | -$0.14+90.3% | -$1.44-227.3% | -$0.44-100.0% | -$0.22 |
PACB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $751.9M-3.9% | $782.4M-0.2% | $784.1M-2.4% | $803.2M-2.7% | $825.5M-4.1% | $860.8M-31.7% | $1.3B-13.1% | $1.5B |
| Current Assets | $338.6M-8.4% | $369.5M-1.5% | $375.1M-4.9% | $394.2M-4.6% | $413.4M-7.1% | $444.9M-10.2% | $495.7M-15.2% | $584.2M |
| Cash & Equivalents | $61.0M+8.4% | $56.3M-11.7% | $63.7M+12.8% | $56.5M+3.0% | $54.8M-6.3% | $58.5M+5.7% | $55.4M-29.0% | $78.0M |
| Inventory | $61.1M+19.7% | $51.0M+3.5% | $49.3M-7.3% | $53.2M-1.3% | $53.8M-0.3% | $54.0M-8.1% | $58.8M-10.6% | $65.7M |
| Accounts Receivable | $31.1M+6.0% | $29.4M-17.2% | $35.4M+15.8% | $30.6M-5.1% | $32.3M+1.9% | $31.6M+15.0% | $27.5M-6.3% | $29.4M |
| Goodwill | $317.8M0.0% | $317.8M0.0% | $317.8M0.0% | $317.8M0.0% | $317.8M0.0% | $317.8M0.0% | $317.8M-13.9% | $369.1M |
| Total Liabilities | $785.1M+0.6% | $780.0M+0.2% | $778.7M+1.5% | $767.1M+0.4% | $764.0M-0.7% | $769.2M+2.0% | $753.9M-24.4% | $996.9M |
| Current Liabilities | $68.8M+5.3% | $65.4M-10.3% | $72.8M+15.2% | $63.2M+5.8% | $59.8M-10.3% | $66.6M+0.5% | $66.3M+10.5% | $60.0M |
| Total Equity | -$33.2M-1503.8% | $2.4M-55.8% | $5.3M-85.2% | $36.1M-41.3% | $61.5M-32.9% | $91.6M-81.9% | $506.6M+11.8% | $453.1M |
| Retained Earnings | -$2.7B-1.7% | -$2.7B-0.3% | -$2.7B-1.5% | -$2.7B-1.5% | -$2.6B-1.6% | -$2.6B-19.8% | -$2.1B+0.1% | -$2.2B |
Not reported in any period shown, so not listed: Long-Term Debt.
PACB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$35.6M+20.4% | -$44.7M-134.4% | -$19.1M-1.9% | -$18.7M+36.3% | -$29.4M+33.3% | -$44.1M-43.7% | -$30.6M+32.6% | -$45.5M |
| Capital Expenditures | $1.6M-48.9% | $3.0M+253.4% | $861K+901.2% | -$86K-84.4% | $550K-60.4% | $1.4M-14.1% | $1.6M+105.5% | -$787K |
| Free Cash Flow | -$37.1M+22.2% | -$47.7M-139.5% | -$19.9M-6.1% | -$18.8M+37.2% | -$29.9M+34.1% | -$45.4M-40.8% | -$32.3M+30.2% | -$46.3M |
| Investing Cash Flow | $40.1M+11.7% | $35.9M+37.8% | $26.0M+37.7% | $18.9M-25.2% | $25.3M-44.1% | $45.2M-22.3% | $58.2M+152.5% | $23.1M |
| Financing Cash Flow | $255K-82.3% | $1.4M | $0-100.0% | $1.5M | $0-100.0% | $2.0M+103.9% | -$50.2M-6282.3% | $812K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PACB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4%-2.1pp | 34.5%-2.6pp | 37.1%-4.3pp | 41.4%+4.4pp | 36.9%+40.6pp | -3.7%-29.3pp | 25.6%+0.6pp | 25.0% |
| Operating Margin | -114.4% | -22.5%+69.8pp | -92.3% | -101.1% | -112.8% | -1154.5% | -390.1% | -160.3% |
| Net Margin | -114.7% | -22.3%+68.2pp | -90.5%+8.4pp | -98.9% | -105.4% | -1146.8% | 5.9% | -151.9% |
| Return on Equity | N/A | -349.8%+405.4pp | -755.2%-649.9pp | -105.3%-37.1pp | -68.2%+396.8pp | -464.9%-465.4pp | 0.5%+13.9pp | -13.4% |
| Return on Assets | -5.9%-4.9pp | -1.1%+4.1pp | -5.1%-0.4pp | -4.7%+0.3pp | -5.1%+44.4pp | -49.5%-49.7pp | 0.2%+4.4pp | -4.2% |
| Current Ratio | 4.92-0.7x | 5.65+0.5x | 5.15-1.1x | 6.24-0.7x | 6.92+0.2x | 6.68-0.8x | 7.48-2.3x | 9.74 |
| Debt-to-Equity | N/A | 329.67+184.1x | 145.59+124.3x | 21.25+8.8x | 12.42+4.0x | 8.39+6.9x | 1.49-0.7x | 2.20 |
| FCF Margin | -95.2% | -128.4% | -44.6%+4.2pp | -48.9%+26.4pp | -75.3% | -122.3% | -82.3% | -115.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Pacific Biosc Ranks
Frequently Asked Questions
What is Pacific Biosc's annual revenue?
Pacific Biosc (PACB) reported $160.0M in total revenue for fiscal year 2025. This represents a 3.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pacific Biosc's revenue growing?
Pacific Biosc (PACB) revenue grew by 3.9% year-over-year, from $154.0M to $160.0M in fiscal year 2025.
Is Pacific Biosc profitable?
No, Pacific Biosc (PACB) reported a net income of -$546.4M in fiscal year 2025.
What is Pacific Biosc's EBITDA?
Pacific Biosc (PACB) had EBITDA of -$171.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Pacific Biosc's gross margin?
Pacific Biosc (PACB) had a gross margin of 28.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Pacific Biosc's return on equity (ROE)?
Pacific Biosc (PACB) has a return on equity of -10215.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pacific Biosc's free cash flow?
Pacific Biosc (PACB) recorded an outflow of $113.9M in free cash flow during fiscal year 2025. This represents a 46.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pacific Biosc's operating cash flow?
Pacific Biosc (PACB) recorded an outflow of $111.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pacific Biosc's total assets?
Pacific Biosc (PACB) had $784.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pacific Biosc's capital expenditures?
Pacific Biosc (PACB) invested $2.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Pacific Biosc spend on research and development?
Pacific Biosc (PACB) invested $97.3M in research and development during fiscal year 2025.
What is Pacific Biosc's current ratio?
Pacific Biosc (PACB) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.
What is Pacific Biosc's debt-to-equity ratio?
Pacific Biosc (PACB) had a debt-to-equity ratio of 145.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pacific Biosc's return on assets (ROA)?
Pacific Biosc (PACB) had a return on assets of -69.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Pacific Biosc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Pacific Biosc (PACB) held $279.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $111.2M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Pacific Biosc's Altman Z-Score?
Pacific Biosc (PACB) has an Altman Z-Score of -6.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Pacific Biosc's Piotroski F-Score?
Pacific Biosc (PACB) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pacific Biosc's earnings high quality?
Pacific Biosc (PACB) reported a net loss of $546.4M while operations used $111.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pacific Biosc cover its interest payments?
Pacific Biosc (PACB) reported an operating loss of $553.9M against $7.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Pacific Biosc?
Pacific Biosc (PACB) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.